# Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

> **NCT00854581** · PHASE4 · TERMINATED · sponsor: **University of Miami** · enrollment: 13 (actual)

## Conditions studied

- Lymphoma
- Precancerous/Nonmalignant Condition

## Interventions

- **BIOLOGICAL:** PEG-interferon alfa-2b
- **BIOLOGICAL:** Interferon alfa-2b
- **DRUG:** Valproic Acid
- **DRUG:** Zidovudine

## Key facts

- **NCT ID:** NCT00854581
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2011-06
- **Final completion:** 2011-11
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Investigator Decision
- **Last updated:** 2018-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854581, "Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00854581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*